Publicaciones en las que colabora con Ana Chopitea Ortega (23)

2024

  1. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials

    BJS open, Vol. 8, Núm. 5

2023

  1. Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience

    Cancers, Vol. 15, Núm. 3

  2. Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma

    Pancreatology, Vol. 23, Núm. 4, pp. 411-419

2019

  1. Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling

    PLoS ONE, Vol. 14, Núm. 5

  2. Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse

    Cancers, Vol. 11, Núm. 5

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  2. Adjuvant therapy for colon cancer: Genes, genes. . . And the patient in the center

    Clinical Cancer Research, Vol. 24, Núm. 16, pp. 3787-3789

  3. Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience

    Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 658-665

2017

  1. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 379-385

2016

  1. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer

    British Journal of Cancer, Vol. 115, Núm. 6, pp. 655-663

2014

  1. Analysis of surgical complications of primary tumor resection after neoadjuvant treatment in stage IV colon cancer

    Journal of Gastrointestinal Oncology, Vol. 5, Núm. 2, pp. 148-153

2013

  1. Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer

    Colorectal Disease, Vol. 15, Núm. 5, pp. 552-557

  2. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy

    Diseases of the Colon and Rectum, Vol. 56, Núm. 4, pp. 416-421

  3. Prognostic factors and prevention of radioembolization-induced liver disease

    Hepatology, Vol. 57, Núm. 3, pp. 1078-1087

2012

  1. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: A validation phase II trial

    International Journal of Radiation Oncology Biology Physics, Vol. 83, Núm. 2, pp. 587-593

2011

  1. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy

    European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847

  2. Patterns of response after preoperative treatment in gastric cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 80, Núm. 3, pp. 698-704

2010

  1. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1529-1535

  2. Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab

    Critical Reviews in Oncology/Hematology, Vol. 74, Núm. 3, pp. 193-202

  3. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis

    British Journal of Cancer, Vol. 102, Núm. 6, pp. 987-994